{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:51:38Z","timestamp":1790682698033,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T00:00:00Z","timestamp":1414627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T00:00:00Z","timestamp":1414627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Tumor necrosis factor (TNF) and, possibly, lymphotoxin alpha (LT\u03b1) signaling contribute to inflammation and rheumatoid arthritis (RA) pathogenesis. Pateclizumab (anti-lymphotoxin- alpha; MLTA3698A) is a humanized monoclonal antibody that blocks and depletes anti-LT\u03b1. This phase 2, randomized, head-to-head, active- and placebo-controlled trial examined the safety and efficacy of pateclizumab compared to adalimumab in RA patients with an inadequate response to disease-modifying antirheumatic drugs (DMARD-IR).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>Patients (<jats:italic>n<\/jats:italic> = 214) with active RA (-6 swollen and tender joints, C-reactive protein -10 mg\/L) on oral DMARDs were randomized (2:2:1) to receive pateclizumab 360 mg, adalimumab 40 mg, or placebo subcutaneously every 2 weeks. The primary endpoint, 4-variable, 28-joint disease activity score erythrocyte sedimentation rate (DAS28(4)-ESR) response, was evaluated at 12 weeks using an analysis of covariance (ANCOVA) model with adjustments for concomitant DMARD use and geographic region. Secondary efficacy endpoints included American College of Rheumatology (ACR) 20, ACR50, and ACR70 responses at Day 85. Pharmacokinetics, pharmacodynamics, and immunogenicity of pateclizumab were assessed.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Pateclizumab reduced the DAS28(4)-ESR response (-1.89) at 12 weeks, however, this did not reach statistical significance compared to placebo (-1.54), while adalimumab (-2.52) differed significantly from both placebo and pateclizumab. Pateclizumab 12-week ACR20, ACR50 and ACR70 response rates (64%, 33%, and 14%) suggested clinical activity but were not statistically significant compared to placebo rates (46%, 24%, and 8%, respectively). CXCL13 serum levels decreased significantly following pateclizumab and adalimumab administration, demonstrating pharmacological target engagement by both drugs. Overall, adverse events (AEs) were comparable among all cohorts. Infections were the most common AE, occurring with comparable frequency in all groups. Serious AEs occurred in 0% of pateclizumab, 5.9% of adalimumab, and 2.3% of placebo patients, with serious infection in 2.3% of adalimumab patients and none in pateclizumab and placebo patients.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Pateclizumab had a good safety profile in patients inadequately responsive to DMARDs, but no statistically significant improvement in RA signs and symptoms after 12 weeks of treatment. Adalimumab demonstrated efficacy and safety comparable to published results in this head-to-head comparison in DMARD-IR RA patients.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Trial registration<\/jats:title>\n                        <jats:p>ClinicalTrials.gov NCT01225393<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\/show\/NCT01225393\">NCT01225393<\/jats:ext-link>, Registered 18 October 2010.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/s13075-014-0467-3","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T18:44:26Z","timestamp":1414608266000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Efficacy and safety of pateclizumab (anti-lymphotoxin-\u03b1) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)"],"prefix":"10.1186","volume":"16","author":[{"given":"William P","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Abraham","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Offutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meina T","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,30]]},"reference":[{"key":"467_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka , van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014, 73: 492-509. 10.1136\/annrheumdis-2013-204573.","journal-title":"Ann Rheum Dis"},{"key":"467_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1600-065X.2008.00633.x","volume":"223","author":"JL Browning","year":"2008","unstructured":"Browning JL: Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunol Rev. 2008, 223: 202-220. 10.1111\/j.1600-065X.2008.00633.x.","journal-title":"Immunol Rev"},{"key":"467_CR3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1146\/annurev.immunol.23.021704.115719","volume":"23","author":"CF Ware","year":"2005","unstructured":"Ware CF: Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol. 2005, 23: 787-819. 10.1146\/annurev.immunol.23.021704.115719.","journal-title":"Annu Rev Immunol"},{"key":"467_CR4","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/nm.1984","volume":"15","author":"EY Chiang","year":"2009","unstructured":"Chiang EY, Kolumam GA, Yu X, Francesco M, Ivelja S, Peng I, Gribling P, Shu J, Lee WP, Refino CJ, Balazs M, Paler-Martinez A, Nguyen A, Young J, Barck KH, Carano RA, Ferrando R, Diehl L, Chatterjea D, Grogan JL: Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med. 2009, 15: 766-773. 10.1038\/nm.1984.","journal-title":"Nat Med"},{"key":"467_CR5","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.4049\/jimmunol.167.2.1072","volume":"167","author":"S Takemura","year":"2001","unstructured":"Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O'Fallon WM, Goronzy JJ, Weyand CM: Lymphoid neogenesis in rheumatoid synovitis. J Immunol. 2001, 167: 1072-1080. 10.4049\/jimmunol.167.2.1072.","journal-title":"J Immunol"},{"key":"467_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1371\/journal.pmed.0060001","volume":"13","author":"F Humby","year":"2009","unstructured":"Humby F, Bombardieri M, Manzo A, Kelly S, Blades MC, Kirkham B, Spencer J, Pitzalis C: Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med. 2009, 13: e1-10.1371\/journal.pmed.0060001.","journal-title":"PLoS Med"},{"key":"467_CR7","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1172\/JCI28756","volume":"116","author":"J Rangel-Moreno","year":"2006","unstructured":"Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M, Randall TD: Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006, 116: 3183-3194. 10.1172\/JCI28756.","journal-title":"J Clin Invest"},{"key":"467_CR8","first-page":"S394","volume":"56","author":"A Baldassare","year":"2007","unstructured":"Baldassare A, Fiechtner J, Filipowicz-Sosnowska A, Jeka S, O'Gorman J, Weaver M, Beckman E: Preliminary safety and efficacy of baminercept (LTBR-Ig, BG9924) in the treatment of rheumatoid arthritis. Arthritis Rheum. 2007, 56: S394-","journal-title":"Arthritis Rheum"},{"key":"467_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/art.24264","volume":"60","author":"MC Genovese","year":"2009","unstructured":"Genovese MC, Greenwald MW, Alloway JA, Baldassare AR, Chase W, Newman C, Weaver ML: Efficacy and safety of baminercept in the treatment of rheumatoid arthritis (RA) results of the phase 2B study in the TNF-IR population. Arthritis Rheum. 2009, 60: 417-10.1002\/art.24264.","journal-title":"Arthritis Rheum"},{"key":"467_CR10","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1136\/ard.2003.009589","volume":"62","author":"R van Vollenhoven","year":"2003","unstructured":"van Vollenhoven R, Harju A, Brannemark S, Klareskog L: Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis. 2003, 62: 1195-1198. 10.1136\/ard.2003.009589.","journal-title":"Ann Rheum Dis"},{"key":"467_CR11","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s10067-008-0880-6","volume":"27","author":"K Laas","year":"2008","unstructured":"Laas K, Peltomaa R, Kautiainen H, Leirisalo-Repo M: Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin Rheumatol. 2008, 27: 927-932. 10.1007\/s10067-008-0880-6.","journal-title":"Clin Rheumatol"},{"key":"467_CR12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP: Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008, 117: 244-279. 10.1016\/j.pharmthera.2007.10.001.","journal-title":"Pharmacol Ther"},{"key":"467_CR13","first-page":"S177","volume":"62","author":"K Chatzidionysiou","year":"2010","unstructured":"Chatzidionysiou K, van Vollenhoven R: TNF switch after failure of one or more TNF inhibitors: results of an observational study. Arthritis Rheum. 2010, 62: S177-","journal-title":"Arthritis Rheum"},{"key":"467_CR14","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1136\/ard.2003.014878","volume":"63","author":"MH Buch","year":"2004","unstructured":"Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P: True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?. Ann Rheum Dis. 2004, 63: 1344-1346. 10.1136\/ard.2003.014878.","journal-title":"Ann Rheum Dis"},{"key":"467_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3109\/03009742.2013.834964","volume":"43","author":"P Nereg\u00e5rd","year":"2013","unstructured":"Nereg\u00e5rd P, Krishnamurthy A, Revu S, Engstr\u00f6m M, af Klint E, Catrina A: Etanercept decreases synovial expression of tumour necrosis factor-\u03b1 and lymphotoxin-\u03b1 in rheumatoid arthritis. Scand J Rheumatol. 2013, 43: 85-90. 10.3109\/03009742.2013.834964.","journal-title":"Scand J Rheumatol"},{"key":"467_CR16","doi-asserted-by":"publisher","first-page":"R6","DOI":"10.1186\/ar3554","volume":"144","author":"B Emu","year":"2012","unstructured":"Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC: Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin \u03b1: results of a phase I randomized, placebo-controlled trial. Arthritis Res Ther. 2012, 144: R6-10.1186\/ar3554.","journal-title":"Arthritis Res Ther"},{"key":"467_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002\/art.1780310302.","journal-title":"Arthritis Rheum"},{"key":"467_CR18","first-page":"1","volume":"59(RR-5)","author":"GH Mazurek","year":"2010","unstructured":"Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K: Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep. 2010, 59(RR-5): 1-25.","journal-title":"MMWR Recomm Rep"},{"key":"467_CR19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38: 444-448. 10.1002\/art.1780380107.","journal-title":"Arthritis Rheum"},{"key":"467_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR: Measurement of patient outcome in arthritis. Arthritis Rheum. 1980, 23: 137-145. 10.1002\/art.1780230202.","journal-title":"Arthritis Rheum"},{"key":"467_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992, 30: 473-483. 10.1097\/00005650-199206000-00002.","journal-title":"Med Care"},{"key":"467_CR22","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1002\/art.23667","volume":"58","author":"I Rioja","year":"2008","unstructured":"Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC: Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum. 2008, 58: 2257-2267. 10.1002\/art.23667.","journal-title":"Arthritis Rheum"},{"key":"467_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/ard.2009.110007","volume":"69","author":"M Boers","year":"2010","unstructured":"Boers M: A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals. Ann Rheum Dis. 2010, 69: 4-6. 10.1136\/ard.2009.110007.","journal-title":"Ann Rheum Dis"},{"key":"467_CR24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1136\/ard.2009.115832","volume":"69","author":"M Boers","year":"2010","unstructured":"Boers M: The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3- and 6-month response rates in trials of biological agents. Ann Rheum Dis. 2010, 69: 186-192. 10.1136\/ard.2009.115832.","journal-title":"Ann Rheum Dis"},{"key":"467_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003, 48: 35-45. 10.1002\/art.10697.","journal-title":"Arthritis Rheum"},{"key":"467_CR26","first-page":"2563","volume":"30","author":"DE Furst","year":"2003","unstructured":"Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003, 30: 2563-2571.","journal-title":"J Rheumatol"},{"key":"467_CR27","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/ard.2003.013052","volume":"63","author":"LB van de Putte","year":"2004","unstructured":"van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H: Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004, 63: 508-516. 10.1136\/ard.2003.013052.","journal-title":"Ann Rheum Dis"},{"key":"467_CR28","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00296-008-0574-z","volume":"28","author":"KP O'Rourke","year":"2008","unstructured":"O'Rourke KP, O'Donoghue G, Adams C, Mulcahy H, Molloy C, Silke C, Molloy M, Shanahan F, O'Gara F: High levels of Lymphotoxin-Beta (LT-Beta) gene expression in rheumatoid arthritis synovium: clinical and cytokine correlations. Rheumatol Int. 2008, 28: 979-986. 10.1007\/s00296-008-0574-z.","journal-title":"Rheumatol Int"},{"key":"467_CR29","first-page":"416","volume":"60","author":"JD Isaacs","year":"2009","unstructured":"Isaacs JD, Genovese MC, Emery P, Scheinberg MA, Spindler AJ, Newman C, Weaver ML, Browning J, O'Gorman J, Cravets M, Hagerty D, Beckman EM, Nirula A: Efficacy and safety of baminercept in the treatment of rheumatoid arthritis (RA). Preliminary results of the phase 2B study in the DMARD-IR population. [abstract]. Arthritis Rheum. 2009, 60: 416-","journal-title":"Arthritis Rheum"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0467-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-014-0467-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0467-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0467-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:25:19Z","timestamp":1728923119000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-014-0467-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,30]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,10]]}},"alternative-id":["467"],"URL":"https:\/\/doi.org\/10.1186\/s13075-014-0467-3","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,30]]},"assertion":[{"value":"3 June 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"467"}}